The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia.
作者： Nora Hamdani , Jean-Pierre Tabeze , Nicolas Ramoz , Jean Ades , Michel Hamon
DOI: 10.1016/J.EURONEURO.2007.05.005
关键词:
摘要: Neurobiological research suggests a significant role of the endocannabinoid system in schizophrenia vulnerability and also quality response to antipsychotics. Genetics offer an opportunity disentangle its involvement disease vs influence on antipsychotics' effects. The possible tag SNP (the 1359G/A polymorphism) gene encoding cannabinoid receptor type 1 (CNR1) and/or therapeutic atypical antipsychotics was assessed cohort 133 French schizophrenic patients compared 141 normal control subjects. No difference polymorphism observed between subjects, no relationships were noted this any clinical parameter considered as potential intermediate factor. However, G allele frequency significantly higher among non-responsive responsive patients, with dose effect allele. In contrast, association found for three other genetic polymorphisms CNR1 gene. could be psychopharmacogenetic rather than factor regarding treatment.
elsevier.com
sci-hub.se 参考文章(41)
Philip Gorwood, Elizabeth Foot, Introduction on psychopharmacogenetics Springer, Boston, MA. pp. 1- 24 ,(2006) , 10.1007/0-387-34577-2_1
Joachim Scharfetter, Psychopharmacogenetics of schizophrenia and psychosis Psychopharmacogenetics. pp. 101- 148 ,(2006) , 10.1007/0-387-34577-2_5
Laqueille X, Dervaux A, Krebs Mo, Lôo H, Olié Jp, Bourdel Mc, Leborgne Mh, [Cannabis and schizophrenia: demographic and clinical correlates]. Encephale-revue De Psychiatrie Clinique Biologique Et Therapeutique. ,vol. 29, pp. 11- 17 ,(2003)
Deepak Cyril D’Souza, Walid Michel Abi-Saab, Steven Madonick, Kimberlee Forselius-Bielen, Anne Doersch, Gabriel Braley, Ralitza Gueorguieva, Thomas B. Cooper, John Harrison Krystal, Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry. ,vol. 57, pp. 594- 608 ,(2005) , 10.1016/J.BIOPSYCH.2004.12.006
U. W. Preuss, G. Koller, P. Zill, B. Bondy, M. Soyka, Alcoholism-related phenotypes and genetic variants of the CB1 receptor. European Archives of Psychiatry and Clinical Neuroscience. ,vol. 253, pp. 275- 280 ,(2003) , 10.1007/S00406-003-0440-7
Nora Hamdani, Mickaël Bonnière, Jean Adès, Michel Hamon, Claudette Boni, Philip Gorwood, Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics Neuroscience Letters. ,vol. 377, pp. 69- 74 ,(2005) , 10.1016/J.NEULET.2004.11.070
John I. Nurnberger, Diagnostic Interview for Genetic Studies Archives of General Psychiatry. ,vol. 51, pp. 849- 859 ,(1994) , 10.1001/ARCHPSYC.1994.03950110009002
Giorgio Marchese, Paola Casti, Stefania Ruiu, PierLuigi Saba, Angela Sanna, GianLuca Casu, Luca Pani, Haloperidol, but not clozapine, produces dramatic catalepsy in Δ9‐THC‐treated rats: possible clinical implications British Journal of Pharmacology. ,vol. 140, pp. 520- 526 ,(2003) , 10.1038/SJ.BJP.0705478
Stanley Lemeshow, David W. Hosmer, Applied Logistic Regression ,(1989)
Emmanuel S. Onaivi, Claire M. Leonard, Hiroki Ishiguro, Ping Wu Zhang, Zhicheng Lin, Babatunde E. Akinshola, George R. Uhl, Endocannabinoids and cannabinoid receptor genetics. Progress in Neurobiology. ,vol. 66, pp. 307- 344 ,(2002) , 10.1016/S0301-0082(02)00007-2